CPC A61K 38/164 (2013.01) [A61K 35/74 (2013.01); A61K 38/443 (2013.01); G01N 33/573 (2013.01); G01N 2333/91255 (2013.01); Y02A 50/30 (2018.01)] | 15 Claims |
1. A method for providing immunosuppression, anti-inflammatory, or anti-infection therapy to a patient in need therefore, the method comprising administering to the patient a pharmaceutical composition comprising an effective amount of an inhibitor of RNA polymerase II, wherein said inhibitor is
(a) an E. coli NlpD protein; or
(b) an active variant of an E. coli NlpD protein having an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 4; or
(c) an E. coli Sigma S protein; or
(d) an active variant of an E. coli Sigma S protein having an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; or
(e) an active fragment of (a), (b), (c), or (d).
|